Retinoblastoma is the most common intraocular malignancy in childhood. Diagnosis is currently made by ophthalmologists under general anesthesia as it is the gold standard for intraocular assessment. However, evaluations for extraocular disease are also necessary. Treatment strategies vary according to the disease status. If a single eye is involved, the treatment goal is oriented to the removal of the tumor and prevention of relapse. In bilateral retinoblastoma, the main treatment goal is to save monocular vision and save life. This article will explore the available treatment options for retinoblastoma including enucleation, radiotherapy, local therapy, intravenous chemotherapy, intra-arterial injection and intra-vitreal injections. There were recent advances in our understanding on the genetic pathophysiology of the retinoblastoma protein gene in tumorigenesis, which may help developing future treatment. Early detection of retinoblastoma is important for prolonging survival and improving quality of life.
Introduction
Retinoblastoma is the most common intraocular malignancy during childhood. This rare malignancy is particular not only because of its severity or peculiarity of diagnosis or treatment due to its privileged location, but because of its genetic characteristics. Since Knudson reported the "two-hit theory", retinoblastoma has attracted many scientists' and physicians' attention as a frontier of cancer genetics [1] . In fact, almost half a century after it was first reported, the pathophysiology of retinoblastoma is not yet fully understood.
The world-wide incidence of retinoblastoma remains stable at nearly 1 case per 15,000-20,000 live births [2] .
Incidence of retinoblastoma in Korea was reported to be 4.99 cases per 100,000 live births [3] .
Genetic and Epigenetic Backgrounds
From the time when the "two-hit theory" was reported, many studies have focused on investigating mutations that affect the expression of the retinoblastoma protein 1 (RB1) gene, which is localized in chromosome 13q14, which encodes for a nuclear phosphoprotein (pRB) [4, 5] . According Vol. 26 , No. 1, April 2019 to this theory, the "first hit" for developing this disease is the inactivation of RB1 by germline mutation. Eventually, other fortuitous events ("second hit") may arise, allowing retinoblastoma to develop through various mechanisms, including non-sense, frameshift, and splice-site mutations, as well as chromosomal instability, loss of heterozygosis, and hypermethylation of promoters [4] . RB1 acts as a tumor-suppressor gene which regulate cell cycle check point between G1 and entry into S phase. However, relation between loss of pRB function and tumorigenesis is not fully understood. Other mechanisms that activate tumorigenesis without RB1 inactivation are currently being explored in mouse-models [5, 6] . These mechanisms are also closely related to other oncogenes or tumor-suppressor genes; gained copies of DEK oncogenes, NUP153, E2F3, TTRAP, copy number variation of MYCN oncogenes are recently discovered cytogenetic lesions in retinoblastoma [4, 6, 7] .
Other epigenetic process in retinoblastoma tumorigenesis also have been found. For example, the spleen tyrosine kinase (SKY) proto-oncogenes, MDM2 and MSM4 in p53 pathways are shown to be increased its expressions in retinoblastoma cells, and its pathways are still under investigation to target potential candidates for future interventions, such as p53 antagonists [8] . Patients with retinoblastoma who have germline mutations in RB1 have a high risk of other secondary malignancies. Osteosarcoma and leukemia are the most common second malignancies in these retinoblastoma patients [9] . Non-inheritable retinoblastoma does not harbor this risk. However, whether patients with somatic mutations, low-level germline mutations, or mosaicism for RB1 have higher risk of second malignancy than non-inheritable retinoblastoma patients is not known [4] .
Clinical Manifestations
Retinoblastoma usually develops in very young infants and neonates, which hinders early detection. Most of retinoblastoma cases are incidentally detected by their parents or family members, observing "cat's eye-like" retinal light-reflection spots in the patient's eyes. "Leukocoria" is the most frequently reported sign and symptom in retinoblastoma, which can also manifest as a "disappearing red spot on photographs". However, leukocoria can be found in other retinal problems such as retinopathy of prematurity, congenital cataract or glaucoma, Coats' disease, toxocariasis, retinal dysplasia, retinal detachments, and persistent fetal vasculature [10] . Confirmation by an experienced ophthalmologist is therefore necessary. Retinoblastoma also manifests as local swelling or inflammation of the involved eye, strabismus, paralysis, and glaucoma [2] .
Diagnosis
When retinoblastoma is suspected, inspection of the eye by an experienced ophthalmologist is necessary. Unlike other malignancies, biopsy procedures are impossible in retinoblastoma patients without enucleation of the organ.
Examination under anesthesia (EUA) is still the gold standard for intraocular assessment [11] . Some efforts to avoid the process of general anesthesia were reported [12] , but until now, EUA is the most precise method to assess the tumor status and apply local treatment simultaneously.
However, having to go under general anesthesia for ten or even hundreds of times is stressful for these young patients and their parents. Ultrasonography and orbital magnetic resonance imaging (MRI) can be additionally used for the evaluation of the tumor extent and extraocular spread.
Since retinoblastoma may involve bone tissue, whole-body bone scans are also important to evaluate external involvement. Orbital and brain MRI are very important radiologic evaluations because involvement of the central nervous system (CNS) indicate different treatment approaches [13, 14] . Cerebrospinal fluid analysis studies are also helpful if CNS involvement is suspected. However, in retinoblastoma, the role of the ophthalmologist is of paramount importance for the adequate diagnosis and treatment of the disease.
Classification and Staging
Retinoblastoma is classified according to various criteria.
According to its growth pattern, it is classified as endophytic or exophytic. Exophytic retinoblastoma grows to- Tumor confined to eye with no optic nerve or choroidal invasion. pT2
Tumor with minimal optic nerve and/or choroidal invasion: pT2a
Tumor superficially invades optic nerve head but does not extend past lamina cribrosa or tumor exhibits focal choroidal invasion. pT2b
Tumor superficially invades optic nerve head but does not extend past lamina cribrosa and exhibits focal choroidal invasion. pT3
Tumor with significant optic nerve and/or choroidal invasion: pT3a
Tumor invades optic nerve past lamina cribrosa but not to surgical resection line or tumor exhibits massive choroidal invasion. pT3b
Tumor invades optic nerve past lamina cribrosa but not to surgical resection line and exhibits massive choroidal invasion. Tumor invades optic nerve to resection line but no extra-ocular extension identified. pT4b
Tumor invades optic nerve to resection line and extra-ocular extension identified. Regional lymph nodes (pN) pNX Regional lymph nodes cannot be assessed pN0
No regional lymph node involvement pN1
Regional lymph node involvement (preauricular, cervical) pN2
Distant lymph node involvement Metastasis (pM) pM0 No metastasis pM1
Metastasis to sites other than CNS pM1a
Single lesion pM1b
Multiple lesions pM1c CNS metastasis pM1d
Discrete mass(es) without leptomeningeal and/or CSF involvement pM1e
Leptomeningeal and/or CSF involvement CNS, central nervous system; CSF, cerebrospinal fluid. ward the outside of the eyeball, and ultimately grows over the eyeball and orbital wall, or involves the optic nerve and eventually, the CNS. It is also called "extraocular retinoblastoma", even though distant metastases are also possible. The TNM staging system proposed by the 7th
American Joint Committee of Cancer (AJCC) ( Table 1) is recommended to assess the disease extent and set the treatment plan [15] . However, "classical" intraocular classification systems are still widely used: the Reese-Ellsworth (R-E) classification (Table 2 ) [16] and the International Intraocular Retinoblastoma Classification System (IIRC, Table 3 ) [17] . The R-E classification was first proposed to assess the extent of intraocular tumor and to assist the decision-making process of enucleation, and to predict the outcome of eternal-beam radiotherapy. The IIRC was proposed much later in the treatment setting of chemotherapy and focal laser therapy. Although these intraocular classifications are used indistinctively, it is recommended to use the IIRC and TNM staging systems. Recently, the International Retinoblastoma Staging System proposed a complement for the focal invasion status, which was not specified in the TNM staging system (Table 4 ) [18] .
Trilateral retinoblastoma is a distinct entity in the classification of retinoblastoma. Trilateral retinoblastoma is a stage in which patients with unilateral or bilateral intraocular retinoblastoma develop intracranial tumors. Some cases of intracranial tumors, not detected at the time of diagnosis, have also been reported [19] . This is a very rare condition, and the prognosis is known to be poor [20] .
Management of trilateral retinoblastoma requires special considerations, which will be discussed later. 
Treatment
In the 1960s, when the R-E classification was first proposed, treatment options for retinoblastoma were enucleation and external-beam radiotherapy [21] . However, the presence of RB1 mutations and the risk of developing secondary malignancies have limited the use of the latter.
Treatment goals in retinoblastoma may be different depending to its extent [2] . Unilateral retinoblastoma shows good prognosis regardless of its severity. Therefore, treatment goal in unilateral retinoblastoma will be saving the 
1) Enucleation
Although sophisticated chemotherapy regimens and local therapies have been developed for several decades, enucleation is still most common treatment, especially in unilateral disease [25] . However, eye enucleation in young children might lead to facial and orbit asymmetry, for which the use of implants and orbital sockets is essential. Reports on neoadjuvant chemotherapy to reduce tumor burden and avoid enucleation showed good responses when combined with local therapy, even in unilateral disease [22, 23] . Since the prognosis of unilateral retinoblastoma is good, delaying enucleation of an eye with severe retinoblastoma (for example, R-E Group Vb, or IIRC Group E) may lead to extraocular spread. Parents usually hesitate when deciding enucleation, and wonder if other options apply. The experienced ophthalmologist should judge the timing of enucleation and the risks and benefits of trying other treatment modalities to save the eye.
2) Radiotherapy
External-beam radiotherapy was the main treatment modality until the 1960s. The eye-saving rate using radiotherapy was reported to be around 58-88%; however, high-grade retinoblastomas (R-E group IV or V) show a low response (＜50%) [26] . Moreover, patients with retinoblastoma and RB1 mutations are susceptible to secondary malignancies [9] . Hence, after molecular diagnostic methods for the clinical detection of RB1 mutations were developed, external-beam radiotherapy has been rarely performed.
However, radiotherapy is a powerful treatment option and should be reserved for stage 4 or severe retinoblastomas that do not respond to other treatment options. In Korea, a single-institution report on external-beam radiotherapy usage showed a 92.3% overall survival rate and a 75.4% of eye-preserving rate [27] . They reported that only 4 of 11 eyes were enucleated in the R-E group IV-V and that the most frequent adverse effects include cataract, retinal detachment, vitreous hemorrhage, and facial asymmetry, but never secondary malignancy [27] . However, this report was based on median 150 months of follow-up periods, and since the risk of secondary malignancy increases 20 years after treatment [28] , relatively short follow-up period should be accounted in interpretation of this result.
The most frequent adverse effect of radiotherapy is on the growth of facial bones, which leads to facial deformities and asymmetries in the orbital walls. Secondary malignancy development after radiotherapy is reported to be 29.7% after a 10-year follow-up [9, 29, 30] . Osteosarcoma and acute myeloid leukemia are the most frequent type of secondary malignancy [9] .
Recently, the use of brachytherapy and proton-beam therapy to avoid unwanted complications of radiotherapy in selected candidates has been reported [31] . Plaque radiotherapy is a kind of brachytherapy in which a small plaque is placed in the targeted eye, and radiation using Iodide However, cryotherapy leaves large scars on the retina and often induces retinal detachment, which can be irreversible [33] .
(2) Laser photocoagulation
Laser photocoagulation therapy can also be applied to multiple small tumors of less than 2-4 mm in diameter.
Laser photocoagulation leaves laser burns on the retina, co- 
4) Systemic chemotherapy
The role of systemic chemotherapy in retinoblastoma was not recognized until the 1970s. Early reports considered chemotherapy in these patients as "neo-adjuvant", being used to reduce the chance of enucleation or reduce the size of the eye to facilitate enucleation. Thereafter, knowing that retinoblastoma cells are sensitive to chemotherapeutic agents, various regimens have been used in extraocular or trilateral retinoblastoma [34, 35] , and even in unilateral retinoblastoma, to avoid enucleation [22, 23] . Chemotherapy regimens usually consist of 6-12 cycles of vincristine, etoposide, and carboplatin in 3-4 week intervals [25, 36] .
If the patient's eye has been enucleated and the pathologic reports reveal optic nerve or extraocular organ involvement, systemic chemotherapy must follow after surgery. In case of distant metastasis, the patient will also require chemotherapy to prevent disease progression and relapse. Extraocular retinoblastoma patients represent 4-20% of the cases and systemic chemotherapy has been reported to protect against disease progression and relapse in these cases [25] .
Recently, high-dose chemotherapy and autologous stem cell transplantation have also been assayed to treat extraocular or high-risk bilateral retinoblastoma patients, increasing survival and decreasing the rate of enucleation [37] . In Korea, 8 out of 9 patients with high-grade bilateral retinoblastoma successfully preserved their eyes when receiving tandem high-dose chemotherapy with autologous stem cell transplantation combined with local therapy [38] . Though 4 patients needed enucleation of one eye, vision was preserved in all of them. However, secondary malignancy issues after high-dose chemotherapy require observation over relatively long periods.
5) Other approaches (1) Intra-arterial chemotherapy
In 2004, Yamane et al. [39] proposed a new procedure consisting in the administration of melphalan through the ophthalmic artery, which feeds the retinoblastoma, and obstructing the end side by ballooning to reduce the re-flow of the chemotherapeutic agent to systemic circulation. They reported that enucleation was avoided in 187 patients with advanced retinoblastoma by "intra-arterial chemotherapy" without any severe complication [39] . After that, many studies have reported using this technique with various chemotherapeutic agents [40, 41] and different artery selection methods [42] . Severe cases, like R-E group V lesions, have also been treated combining local therapies to avoid enucleation. The main complications of intra-arterial chemotherapy are retinal or vitreous hemorrhage, and cotton wool spot near the macula, which might lead to vision loss.
Spasm of the retinal artery may induce local ischemia, which also leads to vision loss. Myositis, resulting in cranial nerve III palsy, has also been rarely reported [25] . nearly 100% rate of saved eyes in high-risk retinoblastoma [35, 45] . Melphalan is the most commonly used chemotherapeutic agent, in various doses [46] . Low doses (8-10 g) show fewer complications, but are less effective than higher doses [35, 46, 47] . In several studies on intravitreal melphalan, intermediate doses of 30-50 g showed effective tumor control with tolerable complications [35, 40, 46] , whereas that higher doses were not recommended because of a less effective anti-tumor effect, and severe toxicity and complications like atrophy of the eye [35, [45] [46] [47] .
The most important complication of intra-vitreal injection is vitreous reflux through the needle, which may lead to tumor spread [35, 48] . Therefore, various efforts to prevent reflux by developing special needles, trimming injection angles, and applying cryotherapy around the injection site have been tested. Retinal detachment, atrophy of macula and retina, vitreous hemorrhage, and atrophy of the eyeball are also important complications, which lead to poor visual outcomes. A recent review reported that poor outcomes
were not a problem of skill, but of wrong selection of chemotherapeutic agents or doses, or a combination of both [35] , which implies that the intervention of well-trained, experienced ophthalmologist is necessary.
Prognosis
Most retinoblastomas show very good survival rates, higher than 90% [2, 10] . Rarely, patients with extraocular disease show poor prognosis [19, 49] . Extraocular disease may re-appear very late after the first diagnosis, so long-term follow-up and examination by both ophthalmologists and pediatric oncologists are warranted [30] .
Extraocular involvement, involvement of the CNS, distant metastasis, relapse, bilateral high-grade retinoblastoma, and trilateral retinoblastoma are risk factors for poor prognosis.
As mentioned earlier, trilateral retinoblastoma shows a very poor prognosis, so a multi-disciplinary approach is needed in such cases [19] .
Quality of life is the major concern when treating retinoblastoma, since preservation of the vision is difficult in most cases of bilateral retinoblastoma.
Long-Term Management
Retinoblastoma requires long-term follow-ups after local therapy. Assessing the eyes through EUA with local therapy, if necessary, is usually recommended in 1-2 months intervals, and if stable, intervals can be increased to 3 months during the first year. Even though tumors are all eradicated, examination in at least 3-month intervals is needed for the first 3 years, then biannual, and annually thereafter [11] . Relapse rates decrease, as the patient gets older.
Assessment of secondary malignancies is also important [9] . RB1 mutation or hereditary retinoblastoma, systemic chemotherapy, radiotherapy, or high-dose chemotherapy with autologous stem cell transplantation are the major risk factors for secondary malignancies. Fifteen to twenty nine years (95% CI=70.0-113.8) after retinoblastoma treatment showed highest risk of developing secondary malignancy [30] . Very late relapse is rare, but also have been reported in Korea [50] . Therefore, long-term follow up and evaluation of patient is important. Education to parents and patients about the risk of secondary malignancy is also important.
Early Detection and Screening
Early detection of retinoblastoma is essential for preserving ocular anatomy and vision. Because patients are very young at diagnosis, usually neonate to their first-year of life, the role of primary health practitioners or pediatricians is vital. The mean age of diagnosis of unilateral and bilateral retinoblastoma in developed countries is within 15 and 27 months, and mortality rates are near 3-5%. However, in developing countries, such as some found in Africa, the mean diagnostic age is close to 25-36 months and mortality can reach up to 70% [10] . This almost 6-month gap of delayed diagnosis might contribute to the high mortality and poor life quality reported for patients of these countries [10] .
Therefore, experts recommend early screening to every children younger than 24 months by primary health providers [51] . The American Academy of Pediatricians recommends screening examination by pediatricians at birth and after the first 3-5 weeks, and then ophthalmologic examinations at 1, 2, 4, 6, 9, 12 15, 18, 24, and 30 months of life, and thereafter, at 3, 4, and 5 years [52] . In Korea, because the National Neonate and Infant Health Examination
Program which includes eye examination for participants who are older than 4 months has been performed, the role of pediatricians in this matter has become more significant.
Genetic counseling and evaluation of the RB1 mutation status of patients and their relatives are also important.
Ninety percent of the patients with bilateral retinoblastoma are found to have RB1 mutations, which are subsequently inherited by their offspring. Among these children, 40% tend to develop retinoblastoma. Siblings of retinoblastoma patients with inheritable mutations also have a 40% risk of developing it [10] . However, children of patients with non-inheritable bilateral retinoblastoma develop the disease in only 6% of the cases. Siblings of these same patients, on the other hand, retain a 40% risk of developing the disease. Likewise, children of patients with non-inheritable retinoblastomas have a certain probability of carrying the mutations. In the case of non-inheritable unilateral retinoblastoma, the risk of the siblings and the offspring developing the disease decreases to 1% and 8%, respectively [10] .
Screenings for family members of the retinoblastoma patient who has RB1 mutations should be performed more frequently than the recommended intervals mentioned above. American academy of ophthalmology recommends every 2 to 4 weeks interval screening at first 2 months, and the monthly examination during the first year after birth, bimonthly in second year, every 3 month after, and every 6 month since 4 year old for families members with RB1 mutation. No screening is needed who are older than 7 year unless having RB1 mutation. Though the family has retinoblastoma patient, if the RB1 mutation is negative, the siblings are at low risk, and only once screening is enough [53] .
Conclusion
Retinoblastoma is a rare disorder, but most common intraocular malignancy in childhood. Understanding the pathophysiology and genetic features of the disease is important when managing these patients and their relatives. Recent advances in various technologies have improved, not also survival, but also preservation of vision and quality of life.
However, still, early detection of the disease is the most important factor for optimal management of retinoblastoma.
